Jump Financial LLC Acquires 77,699 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Jump Financial LLC raised its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 80.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 173,890 shares of the company's stock after acquiring an additional 77,699 shares during the quarter. Jump Financial LLC owned approximately 0.20% of Syndax Pharmaceuticals worth $2,299,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Stifel Financial Corp bought a new stake in Syndax Pharmaceuticals during the third quarter valued at about $327,000. Barclays PLC increased its position in shares of Syndax Pharmaceuticals by 143.4% during the third quarter. Barclays PLC now owns 187,629 shares of the company's stock valued at $3,612,000 after acquiring an additional 110,535 shares during the last quarter. Geode Capital Management LLC lifted its stake in Syndax Pharmaceuticals by 3.5% in the third quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company's stock worth $38,066,000 after acquiring an additional 66,459 shares during the last quarter. Sanctuary Advisors LLC acquired a new stake in Syndax Pharmaceuticals during the 3rd quarter worth $595,000. Finally, Franklin Resources Inc. grew its holdings in shares of Syndax Pharmaceuticals by 13.4% during the third quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company's stock worth $34,948,000 after purchasing an additional 208,043 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. StockNews.com raised Syndax Pharmaceuticals to a "sell" rating in a research note on Thursday, April 10th. Citigroup decreased their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. JPMorgan Chase & Co. boosted their price target on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research report on Thursday, March 20th. Scotiabank lowered their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research note on Wednesday, January 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $36.20.

Insider Activity

In related news, CFO Keith A. Goldan sold 3,777 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the completion of the sale, the chief financial officer now owns 90,746 shares of the company's stock, valued at approximately $1,406,563. This trade represents a 4.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the transaction, the chief executive officer now directly owns 300,121 shares in the company, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,683 shares of company stock worth $336,087. Insiders own 4.10% of the company's stock.

Syndax Pharmaceuticals Stock Up 0.6 %

SNDX traded up $0.08 during trading on Thursday, hitting $13.08. The company had a trading volume of 254,989 shares, compared to its average volume of 1,587,300. The firm's 50-day moving average price is $13.13 and its 200 day moving average price is $14.96. Syndax Pharmaceuticals, Inc. has a one year low of $9.66 and a one year high of $25.07. The company has a market capitalization of $1.13 billion, a PE ratio of -3.60 and a beta of 1.28.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to the consensus estimate of $86.32 million. Sell-side analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).